NewAmsterdam Pharma (NAMS) Debt to Equity (2022 - 2025)
NewAmsterdam Pharma (NAMS) has disclosed Debt to Equity for 4 consecutive years, with $0.08 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 69.21% to $0.08 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.08 through Dec 2025, up 69.21% year-over-year, with the annual reading at $0.08 for FY2025, 69.21% up from the prior year.
- Debt to Equity hit $0.08 in Q4 2025 for NewAmsterdam Pharma, up from $0.06 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.08 in Q4 2025 to a low of $0.01 in Q4 2022.
- Historically, Debt to Equity has averaged $0.05 across 4 years, with a median of $0.05 in 2024.
- Biggest five-year swings in Debt to Equity: surged 419.72% in 2023 and later crashed 62.31% in 2025.
- Year by year, Debt to Equity stood at $0.01 in 2022, then soared by 419.72% to $0.04 in 2023, then increased by 13.59% to $0.05 in 2024, then surged by 69.21% to $0.08 in 2025.
- Business Quant data shows Debt to Equity for NAMS at $0.08 in Q4 2025, $0.06 in Q3 2025, and $0.03 in Q2 2025.